Bluejay Diagnostics, Inc.

Bluejay Diagnostics, Inc.

NNASDAQ:BJDX
2.29
USD
-0.32
(-12.26%)
-8.06EPS
4.97MMarket Cap
Mar 23Next Earn

Total Valuation

USD

As of June 30, 2026, Bluejay Diagnostics, Inc. carries a market capitalization of 4.97M, placing it among publicly traded companies globally. Its enterprise value stands at -4.56M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.97M
Enterprise Value-4.56M

Important Dates

Bluejay Diagnostics, Inc.'s next confirmed earnings release is scheduled for March 23, 2027.

Earnings Date3/23/2027

Share Statistics

As of June 30, 2026, Bluejay Diagnostics, Inc. has 1.03M shares outstanding.

Shares Outstanding1.03M

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio0.53
P/TBV Ratio0.53
P/FCF Ratio-0.69
P/OCF Ratio-0.73

Financial Position

As of June 30, 2026, Bluejay Diagnostics, Inc. maintains a current ratio of 4.64, meaning it holds 4.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.78, indicating moderate leverage, while an interest coverage ratio of -18,569.15 demonstrates limited ability to service its debt obligations.

Current Ratio4.64
Quick Ratio4.53
Debt / Equity0.78
Debt / EBITDA-0.01
Interest Coverage-18,569.15

Financial Efficiency

Over the twelve months ended June 30, 2026, Bluejay Diagnostics, Inc. posted a negative return on equity (ROE) of -98.89, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -81.07, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 6.25, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-98.89
Return on Assets (ROA)-81.07
Employee Count6.25

Stock Price Statistics

USD

As of the close on November 16, 2026, Bluejay Diagnostics, Inc.'s stock has declined approximately 90.33% over the past 52 weeks. The 50-day moving average sits at 3.05, while the 200-day moving average is 6.83.

52-Week Price Change-90.33%
50-Day Moving Average3.05
200-Day Moving Average6.83

Income Statement

USD

Over the twelve months ended June 30, 2026, Bluejay Diagnostics, Inc. generated - - in revenue and converted that into -7.27M in net income, yielding earnings per share of -8.06. EBITDA reached -7.19M, while operating income came in at -7.37M.

Operating Income-7.37M
Pretax Income-7.27M
Net Income-7.27M
EBITDA-7.19M
EBIT-7.37M
Earnings Per Share (EPS)-8.06

Balance Sheet

USD

As of June 30, 2026, Bluejay Diagnostics, Inc. holds 9.60M in cash and equivalents against 73,444.00 in total debt, resulting in a net debt position of -9.60M. Total book value stands at 9.41M, with working capital of 7.70M providing operational flexibility.

Cash & Cash Equivalents9.60M
Total Debt73,444.00
Net Debt-9.60M
Equity (Book Value)9.41M
Book Value Per Share9.10
Working Capital7.70M

Cash Flow

USD

Bluejay Diagnostics, Inc. produced -5.90M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -335,497.00 in capital expenditures, free cash flow totaled -6.24M - equivalent to -6.92 per share.

Operating Cash Flow-5.90M
Capital Expenditures-335,497.00
Free Cash Flow-6.24M
FCF Per Share-6.92

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -144.07: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -229.35, meaning Bluejay Diagnostics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-229.35
FCF Yield-144.07

Stock Splits

Bluejay Diagnostics, Inc.'s most recent stock split took place on November 3, 2026 with a 4:1 split ratio.

Last Split Date11/3/2026
Split Ratio4:1

Scores

As of June 30, 2026, Bluejay Diagnostics, Inc. has an Altman Z-Score of -5.45, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-5.45